A noninvasive blood-based combinatorial proteomic biomarker assay to detect breast cancer in women over age 50 with BI-RADS 3, 4, or 5 Assessment

Meredith C. Henderson, Michael Silver, Quynh Tran, Elias E. Letsios, Rao Mulpuri, David E. Reese, Ana P. Lourenco, Joshua LaBaer, Karen S. Anderson, Josie Alpers, Carrie Costantini, Nitin Rohatgi, Haythem Ali, Karen Baker, Donald W Northfelt, Karthik Ghosh, Stephen R. Grobmyer, Winnie Polen, Judith K. Wolf

Research output: Contribution to journalArticle

Abstract

Purpose: With improvements in breast cancer imaging, there has been a corresponding increase in false-positives and avoidable biopsies. There is a need to better differentiate when a breast biopsy is warranted and determine appropriate follow-up. This study describes the design and clinical performance of a combinatorial proteomic biomarker assay (CPBA), Videssa Breast, in women over age 50 years. Experimental Design: A BI-RADS 3, 4, or 5 assessment was required for clinical trial enrollment. Serum was collected prior to breast biopsy and subjects were followed for 6–12 months and clinically relevant outcomes were recorded. Samples were split into training (70%) and validation (30%) cohorts with an approximate 1:4 case:control ratio in both arms. Results: A CPBA that combines biomarker data with patient clinical data was developed using a training cohort (469 women, cancer incidence: 18.5%), resulting in 94% sensitivity and 97% negative predictive value (NPV). Independent validation of the final algorithm in 194 subjects (breast cancer incidence: 19.6%) demonstrated a sensitivity of 95% and a NPV of 97%. When combined with previously published data for women under age 50, Videssa Breast achieves a comprehensive 93% sensitivity and 98% NPV in a population of women ages 25–75. Had Videssa Breast results been incorporated into the clinical workflow, approximately 45% of biopsies might have been avoided. Conclusions: Videssa Breast combines serum biomarkers with clinical patient characteristics to provide clinicians with additional information for patients with indeterminate breast imaging results, potentially reducing false-positive breast biopsies.

Original languageEnglish (US)
Pages (from-to)142-149
Number of pages8
JournalClinical Cancer Research
Volume25
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Proteomics
Breast
Biomarkers
Breast Neoplasms
Biopsy
Workflow
Incidence
Serum
Arm
Research Design
Clinical Trials
Population
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A noninvasive blood-based combinatorial proteomic biomarker assay to detect breast cancer in women over age 50 with BI-RADS 3, 4, or 5 Assessment. / Henderson, Meredith C.; Silver, Michael; Tran, Quynh; Letsios, Elias E.; Mulpuri, Rao; Reese, David E.; Lourenco, Ana P.; LaBaer, Joshua; Anderson, Karen S.; Alpers, Josie; Costantini, Carrie; Rohatgi, Nitin; Ali, Haythem; Baker, Karen; Northfelt, Donald W; Ghosh, Karthik; Grobmyer, Stephen R.; Polen, Winnie; Wolf, Judith K.

In: Clinical Cancer Research, Vol. 25, No. 1, 01.01.2019, p. 142-149.

Research output: Contribution to journalArticle

Henderson, MC, Silver, M, Tran, Q, Letsios, EE, Mulpuri, R, Reese, DE, Lourenco, AP, LaBaer, J, Anderson, KS, Alpers, J, Costantini, C, Rohatgi, N, Ali, H, Baker, K, Northfelt, DW, Ghosh, K, Grobmyer, SR, Polen, W & Wolf, JK 2019, 'A noninvasive blood-based combinatorial proteomic biomarker assay to detect breast cancer in women over age 50 with BI-RADS 3, 4, or 5 Assessment' Clinical Cancer Research, vol. 25, no. 1, pp. 142-149. https://doi.org/10.1158/1078-0432.CCR-18-0843
Henderson, Meredith C. ; Silver, Michael ; Tran, Quynh ; Letsios, Elias E. ; Mulpuri, Rao ; Reese, David E. ; Lourenco, Ana P. ; LaBaer, Joshua ; Anderson, Karen S. ; Alpers, Josie ; Costantini, Carrie ; Rohatgi, Nitin ; Ali, Haythem ; Baker, Karen ; Northfelt, Donald W ; Ghosh, Karthik ; Grobmyer, Stephen R. ; Polen, Winnie ; Wolf, Judith K. / A noninvasive blood-based combinatorial proteomic biomarker assay to detect breast cancer in women over age 50 with BI-RADS 3, 4, or 5 Assessment. In: Clinical Cancer Research. 2019 ; Vol. 25, No. 1. pp. 142-149.
@article{a491b97892e449cabfe1eedd09103db7,
title = "A noninvasive blood-based combinatorial proteomic biomarker assay to detect breast cancer in women over age 50 with BI-RADS 3, 4, or 5 Assessment",
abstract = "Purpose: With improvements in breast cancer imaging, there has been a corresponding increase in false-positives and avoidable biopsies. There is a need to better differentiate when a breast biopsy is warranted and determine appropriate follow-up. This study describes the design and clinical performance of a combinatorial proteomic biomarker assay (CPBA), Videssa Breast, in women over age 50 years. Experimental Design: A BI-RADS 3, 4, or 5 assessment was required for clinical trial enrollment. Serum was collected prior to breast biopsy and subjects were followed for 6–12 months and clinically relevant outcomes were recorded. Samples were split into training (70{\%}) and validation (30{\%}) cohorts with an approximate 1:4 case:control ratio in both arms. Results: A CPBA that combines biomarker data with patient clinical data was developed using a training cohort (469 women, cancer incidence: 18.5{\%}), resulting in 94{\%} sensitivity and 97{\%} negative predictive value (NPV). Independent validation of the final algorithm in 194 subjects (breast cancer incidence: 19.6{\%}) demonstrated a sensitivity of 95{\%} and a NPV of 97{\%}. When combined with previously published data for women under age 50, Videssa Breast achieves a comprehensive 93{\%} sensitivity and 98{\%} NPV in a population of women ages 25–75. Had Videssa Breast results been incorporated into the clinical workflow, approximately 45{\%} of biopsies might have been avoided. Conclusions: Videssa Breast combines serum biomarkers with clinical patient characteristics to provide clinicians with additional information for patients with indeterminate breast imaging results, potentially reducing false-positive breast biopsies.",
author = "Henderson, {Meredith C.} and Michael Silver and Quynh Tran and Letsios, {Elias E.} and Rao Mulpuri and Reese, {David E.} and Lourenco, {Ana P.} and Joshua LaBaer and Anderson, {Karen S.} and Josie Alpers and Carrie Costantini and Nitin Rohatgi and Haythem Ali and Karen Baker and Northfelt, {Donald W} and Karthik Ghosh and Grobmyer, {Stephen R.} and Winnie Polen and Wolf, {Judith K.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1158/1078-0432.CCR-18-0843",
language = "English (US)",
volume = "25",
pages = "142--149",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - A noninvasive blood-based combinatorial proteomic biomarker assay to detect breast cancer in women over age 50 with BI-RADS 3, 4, or 5 Assessment

AU - Henderson, Meredith C.

AU - Silver, Michael

AU - Tran, Quynh

AU - Letsios, Elias E.

AU - Mulpuri, Rao

AU - Reese, David E.

AU - Lourenco, Ana P.

AU - LaBaer, Joshua

AU - Anderson, Karen S.

AU - Alpers, Josie

AU - Costantini, Carrie

AU - Rohatgi, Nitin

AU - Ali, Haythem

AU - Baker, Karen

AU - Northfelt, Donald W

AU - Ghosh, Karthik

AU - Grobmyer, Stephen R.

AU - Polen, Winnie

AU - Wolf, Judith K.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: With improvements in breast cancer imaging, there has been a corresponding increase in false-positives and avoidable biopsies. There is a need to better differentiate when a breast biopsy is warranted and determine appropriate follow-up. This study describes the design and clinical performance of a combinatorial proteomic biomarker assay (CPBA), Videssa Breast, in women over age 50 years. Experimental Design: A BI-RADS 3, 4, or 5 assessment was required for clinical trial enrollment. Serum was collected prior to breast biopsy and subjects were followed for 6–12 months and clinically relevant outcomes were recorded. Samples were split into training (70%) and validation (30%) cohorts with an approximate 1:4 case:control ratio in both arms. Results: A CPBA that combines biomarker data with patient clinical data was developed using a training cohort (469 women, cancer incidence: 18.5%), resulting in 94% sensitivity and 97% negative predictive value (NPV). Independent validation of the final algorithm in 194 subjects (breast cancer incidence: 19.6%) demonstrated a sensitivity of 95% and a NPV of 97%. When combined with previously published data for women under age 50, Videssa Breast achieves a comprehensive 93% sensitivity and 98% NPV in a population of women ages 25–75. Had Videssa Breast results been incorporated into the clinical workflow, approximately 45% of biopsies might have been avoided. Conclusions: Videssa Breast combines serum biomarkers with clinical patient characteristics to provide clinicians with additional information for patients with indeterminate breast imaging results, potentially reducing false-positive breast biopsies.

AB - Purpose: With improvements in breast cancer imaging, there has been a corresponding increase in false-positives and avoidable biopsies. There is a need to better differentiate when a breast biopsy is warranted and determine appropriate follow-up. This study describes the design and clinical performance of a combinatorial proteomic biomarker assay (CPBA), Videssa Breast, in women over age 50 years. Experimental Design: A BI-RADS 3, 4, or 5 assessment was required for clinical trial enrollment. Serum was collected prior to breast biopsy and subjects were followed for 6–12 months and clinically relevant outcomes were recorded. Samples were split into training (70%) and validation (30%) cohorts with an approximate 1:4 case:control ratio in both arms. Results: A CPBA that combines biomarker data with patient clinical data was developed using a training cohort (469 women, cancer incidence: 18.5%), resulting in 94% sensitivity and 97% negative predictive value (NPV). Independent validation of the final algorithm in 194 subjects (breast cancer incidence: 19.6%) demonstrated a sensitivity of 95% and a NPV of 97%. When combined with previously published data for women under age 50, Videssa Breast achieves a comprehensive 93% sensitivity and 98% NPV in a population of women ages 25–75. Had Videssa Breast results been incorporated into the clinical workflow, approximately 45% of biopsies might have been avoided. Conclusions: Videssa Breast combines serum biomarkers with clinical patient characteristics to provide clinicians with additional information for patients with indeterminate breast imaging results, potentially reducing false-positive breast biopsies.

UR - http://www.scopus.com/inward/record.url?scp=85059449351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059449351&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-18-0843

DO - 10.1158/1078-0432.CCR-18-0843

M3 - Article

VL - 25

SP - 142

EP - 149

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 1

ER -